Pazopanib-13C,d3 hydrochloride structure
|
Common Name | Pazopanib-13C,d3 hydrochloride | ||
---|---|---|---|---|
CAS Number | 1261398-44-0 | Molecular Weight | 477.990 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C2013CH21D3ClN7O2S | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Pazopanib-13C,d3 hydrochloridePazopanib-13C,d3 (hydrochloride) is the deuterium and 13C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3]. |
Name | 5-[(4-{(2,3-Dimethyl-2H-indazol-6-yl)[(13C,2H3)methyl]amino}-2-pyrimidinyl)amino]-2-methylbenzenesulfonamide hydrochloride (1:1) |
---|---|
Synonym | More Synonyms |
Description | Pazopanib-13C,d3 (hydrochloride) is the deuterium and 13C labeled Pazopanib hydrochloride[1]. Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms with an IC50 of 10, 30, 47, 84, 74, 140 and 146 nM, respectively[2][3]. |
---|---|
Related Catalog | |
In Vitro | Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1]. |
References |
Molecular Formula | C2013CH21D3ClN7O2S |
---|---|
Molecular Weight | 477.990 |
Exact Mass | 477.162262 |
Benzenesulfonamide, 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methyl-13C-d3-amino]-2-pyrimidinyl]amino]-2-methyl-, hydrochloride (1:1) |
5-[(4-{(2,3-Dimethyl-2H-indazol-6-yl)[(13C,2H3)methyl]amino}-2-pyrimidinyl)amino]-2-methylbenzenesulfonamide hydrochloride (1:1) |